ABC | Volume 113, Nº4, October 2019

Original Article Abolhasani et al. Serum levels of markers in CAD prediction Arq Bras Cardiol. 2019; 113(4):667-674 1. Finegold JA, Asaria P, Francis DP. Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol. 2013;168(2):934-45. 2. Itabe H, Obama T, Kato R. The dynamics of oxidized LDL during atherogenesis. J Lipids. 2011;2011:418313. 3. Derer W, Barnathan ES, Safak E, Agarwal P, Heidecke H, Möckel M, et al. Vitronectin concentrations predict risk in patients undergoing coronary stenting. Circ Cardiovasc Interv. 2009;2(1):14-9. 4. Prasad K. C-Reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev. 2006;24(1):33-50. 5. Varma V, Varma M, Varma A, Kumar R, Bharosay A, Vyas S. Serum total sialic acid and highly sensitive C-reactive protein: Prognostic markers for the diabetic nephropathy. J Lab Physicians. 2016;8(1):25-9. 6. Vitulli P, Tanzilli G, Marullo AG, Peruzzi M, Zoccai GB. Inflammation and oxidative stress in acute coronary syndromes: a continuum from plaque vulnerabilitytothrombus formation.EnlivenClinCardiolRes.2014;1(1):1-7. 7. Ferrari E, Lutgens E, Weber C, Gerdes N. Atherosclerosis: cell biology and lipoproteins focus on epigeneticmodification andmacrophage biology. Curr Opin Lipidol. 2017;28(2):220-1. 8. Zhao X, Zhang HW, Xu RX, Guo YL, Zhu CG, Wu NQ, et al. Oxidized-LDL is a useful marker for predicting the very early coronary artery disease and cardiovascular outcomes. Per Med. 2018;15(6):521-9. 9. Ekmekçi ÖB, Ekmekçi H. Vitronectin in atherosclerotic disease. Clin Chim Acta. 2006;368(1-2):77-83. 10. Ekmekci H, Sonmez H, Ekmekci OB, Ozturk Z, Domanic N, Kokoglu E. Plasma vitronectin levels in patients with coronary atherosclerosis are increased and correlate with extent of disease. J Thromb Thrombolysis. 2002;14(3):221-5. 11. Yaghoubi A, Ghojazadeh M, Abolhasani S, Alikhah H, Khaki-Khatibi F. Correlation of serum levels of vitronectin, malondialdehyde and Hs-CRP with disease severity in coronary artery disease. J Cardiovasc Thorac Res. 2015;7(3):113-7. 12. Tjärnlund-WolfA,BrogrenH,LoEH,WangX.Plasminogenactivatorinhibitor-1 and thrombotic cerebrovascular diseases. Stroke. 2012;43(10):2833-9. 13. Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther. 2010;28(5):e72-91. 14. Govindarajan S, Raghavan VM, Rao ACV. PlasmaMyeloperoxidase and total sialic acid as prognostic indicators in acute coronary syndrome. J ClinDiagn Res. 2016;10(8):BC09-13. 15. Khaki-Khatibi F, Sadeghi Z, Yaghoubi A, Ashoori MR, Gharebaba RP. Relationship between serum levels of total sialic acid, mda-ldl, and hs-crp with extension of coronary artery disease, in nonsmoker and nondiabetic patients. World J Pharm Pharm Sci. 2015;5(2);294-305. 16. Gökmen SS, Kiliçli G, Özçelik F, Gülen S.. Serum total and lipid-bound sialic acid levels following acute myocardial infarction. Clin Chem Lab Med. 2000;38(12):1249-55. 17. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord. 2010;125(1):287-94. 18. Chen C, Khismatullin DB. Oxidized low-density lipoprotein contributes to atherogenesis via co-activation of macrophages and mast cells. PloS One. 2015;10(3):e0123088. 19. Galkina E, Ley K. Immune and inflammatorymechanisms of atherosclerosis. Annu Rev Immunol. 2009;27:165-97. 20. Khaki-Khatibi F, Mahmoodi N, Abolhasani S, Gharebaba RP. Correlation of fibrinolysis marker of plasma plasminogen activator inhibitor type-1 and oxidative stress parameters in occurrence and progression of coronary artery disease. Bull Env Pharmacol Life Sci. 2014;3(7):27-33. 21. Khaki-Khatibi F, Gharebaba RP, Yaghoubi A, Farajzade A, Mahmoodi N, Abolhasani S. Relationship between serum levels of fibronectin, leptin and hs-CRP with extension of coronary artery disease. Bull Env Pharmacol Life Sci. 2014;3(7):40-6. 22. Singh RB, Mengi SA, Xu YJ, Arneja AS, Dhalla NS. Pathogenesis of atherosclerosis: amultifactorial process. Exp Clin Cardiol. 2002;7(1):40-53. 23. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol. 2003;91(3A):3A-6A. 24. NigamPK,NarainVS,ChandraN,PuriVK,SaranRK,DwivedSK,etal.Serum and platelet sialic acid in acutemyocardial infarction. Indian J Clin Biochem. 1995;10(2):106-9. 25. Dufourcq P, Louis H, Moreau C, Daret D, Boisseau M, Lamazière JMD, et al. Vitronectinexpressionandinteractionwithreceptorsinsmoothmusclecellsfrom humanatheromatousplaque.ArteriosclerThrombVascBiol.1998;18(2):168-76. 26. LuoM, Ji Y, Luo Y, Li R,FayWP,Wu J. Plasminogen activator inhibitor-1regulates thevascularexpressionofvitronectin.JThrombHaemost.2017;15(12):2451-60. 27. CaoDJ,GuoYL,ColmanRW.Urokinase-typeplasminogenactivatorreceptor is involved inmediatingtheapoptoticeffectofcleavedhighmolecularweight kininogen in human endothelial cells. Circ Res. 2004;94(9):1227-34. 28. Forood A, Malekpour-Afshar R, Mahdavi A. Serum level of plasminogen activator inhibitor type-1 in addicted patients with coronary artery disease. Addict Health. 2014;6(3-4):119-26. 29. Båvenholm P, De Faire U, Landou C, Efendic S, Nilsson J, Wiman B, et al. Progression of coronary artery disease in youngmale post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. Eur Heart J. 1998;19(3):402-10. 30. Naya M, Tsukamoto T, Inubushi M, Morita K, Katoh C, Furumoto T, et al. Elevated plasma plasminogen activator inhibitor type-1 is an independent predictor of coronary microvascular dysfunction in hypertension. Circ J. 2007;71(3):348-53. 31. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2001;21(5):844-8. 32. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103(15):1955-60. 33. Crook M, Lumb P, Andrews V, Swaminathan R. Serum total sialic acid, a reputed cardiovascular risk factor, and its relationship to lipids, plasma fasting insulin, blood pressure and body mass index in normal individuals. Clin Sci. 1998;95(1):53-7. 34. Serdar Z, Serdar A, Altin A, Eryilmaz U, Albayrak S. The relation between oxidant and antioxidant parameters and severity of acute coronary syndromes. Acta Cardiol. 2007;62(4):373-80. 35. KnuimanMW,Watts GF, Divitini ML. Is sialic acid an independent risk factor for cardiovascular disease? A 17-year follow-up study in Busselton, Western Australia. Ann Epidemiol. 2004;14(9):627-32. 36. Ghodke SS, Padalkar RK, Bhagat SS. hs-CRP: A” golden marker” of inflammationandcoronaryarterydisease.IntJHealthSciRes.2012;2(6):42-6. 37. Sharma SB, Garg S, Veerwal A, Dwivedi S. hs-CRP and oxidative stress in young CADpatients: a pilot study Indian J Clin Biochem. 2008;23(4):334-6. 38. Mahajan N, Malik N, Bahl A, Sharma Y, Dhawan V. Correlation among soluble markers and severity of disease in non-diabetic subjects with pre- mature coronary artery disease. Mol Cell Biochem. 2009;330(1-2):201-9. 39. Arroyo-Espliguero R, Avanzas P, Cosín-Sales J, Aldama G, Pizzi C, Kaski JC. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004;25(5):401-8. References 673